Dissection of the human multipotent adult progenitor cell secretome by proteomic analysis

Stem Cells Translational Medicine

Volumn 2, Issue 10, 2013, Pages 745-757

  Burrows, Gregory G ^a,b   Van't Hof, Wouter ^c,d,e   Newell, Laura F ^a   Reddy, Ashok ^b   Wilmarth, Phillip A ^b   David, Larry L ^b   Raber, Amy ^c   Bogaerts, Annelies ^d,e   Pinxteren, Jef ^d,e   Deans, Robert J ^c,d,e   Maziarz, Richard T ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c ATHERSYS INC   (United States)

^d National Center for Regenerative Medicine   (United States)

^e ReGenesys   (Belgium)

Author keywords

Adult hematopoietic stem cells; Graft versus host disease; Immunotherapy; Mesenchymal stem cells; Proteomics; RTL1000; Tolerance

Indexed keywords

5' NUCLEOTIDASE; ANGIOPOIETIN RECEPTOR; BIGLYCAN; CADHERIN; CATHEPSIN B; CONNECTIVE TISSUE GROWTH FACTOR; DECORIN; ENDOGLIN; ENTACTIN; FOLLISTATIN RELATED PROTEIN; GALECTIN 1; GAMMA INTERFERON; GELATINASE A; GROWTH FACTOR; INTERSTITIAL COLLAGENASE; LAMININ; LIPOPOLYSACCHARIDE; OSTEOPONTIN; PROTEASE NEXIN I; PROTEINASE; SOMATOMEDIN; T LYMPHOCYTE RECEPTOR; THROMBOSPONDIN 1; THROMBOSPONDIN 2; THY 1 ANTIGEN; TRANSCRIPTION FACTOR RUNX2; UNINDEXED DRUG; UROKINASE RECEPTOR; VASCULOTROPIN; VERSICAN;

ANGIOGENESIS; ARTICLE; ELECTROSPRAY MASS SPECTROMETRY; EXTRACELLULAR MATRIX; FOLLOW UP; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOCOMPATIBILITY COMPLEX; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; MICROARRAY ANALYSIS; MULTIPOTENT STEM CELL; PROTEOMICS; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REVERSED PHASE LIQUID CHROMATOGRAPHY;

EID: 84884755521     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2013-0031     Document Type: Article

References (128)

1. Biernaskie J, Sparling JS, Liu J et al. Skinderived precursors generate myelinating Schwann cells that promote remyelination and functional recovery after contusion spinal cord injury. J Neurosci 2007;27:9545-9559.
2. Bambakidis NC, Butler J, Horn EM et al. Stem cell biology and its therapeutic applications in the setting of spinal cord injury. Neurosurg Focus 2008;24:E20.
3. Barnabé-Heider F, Frisen J. Stem cells for spinal cord repair. Cell Stem Cell 2008;3:16-24.
4. Le Blanc K, Frassoni F, Ball L et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. Lancet 2008;371:1579-1586.
5. Kebriaei P, Robinson S. Treatment of graft-versus-host-disease with mesenchymal stromal cells. Cytotherapy 2011;13:262-268.
6. Reading JL, Yang JH, Sabbah S et al. Clinical-grade multipotent adult progenitor cells durably control pathogenic T cell responses in human models of transplantation and autoimmunity. J Immunol 2013;190:4542-4552.
7. Gnecchi M, Zhang Z, Ni A et al. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res 2008;103:1204-1219.
8. Kebriaei P, Isola L, Bahceci E et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 2009;15:804-811.
9. Auletta JJ, Deans RJ, Bartholomew AM. Emerging roles for multipotent, bone marrowderived stromal cells in host defense. Blood 2012;119:1801-1809.
10. Caplan AI. All MSCs are pericytes? Cell Stem Cell 2008;3:229-230.
11. Jiang Y, Jahagirdar BN, Reinhardt RL et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002;418: 41-49.
12. Anjos-Afonso F, Bonnet D. Nonhematopoietic/ endothelial SSEA-1+ cells define the most primitive progenitors in the adult murine bone marrow mesenchymal compartment. Blood 2007;109:1298-1306.
13. D'Ippolito G, Diabira S, Howard GA et al. Marrow-isolated adult multilineage inducible (MIAMI) cells, a unique population of postnatal young and old human cells with extensive expansion and differentiation potential. J Cell Sci 2004;117:2971-2981.
14. Reyes M, Lund T, Lenvik T et al. Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells. Blood 2001;98:2615-2625.
15. Kovacsovics-Bankowski M, Mauch K, Raber A et al. Pre-clinical safety testing supporting clinical use of allogeneic multipotent adult progenitor cells. Cytotherapy 2008;10: 730-742.
16. Kovacsovics-Bankowski M, Streeter PR, Mauch KA et al. Clinical scale expanded adult pluripotent stem cells prevent graftversus-host disease. Cell Immunol 2009;255: 55-60.
17. Pevsner-Fischer M, Morad V, Cohen-Sfady M et al. Toll-like receptors and their ligands control mesenchymal stem cell functions. Blood 2007;109:1422-1432.
18. Krampera M, Cosmi L, Angeli R et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006;24:386-398.
19. Barrilleaux BL, Fischer-Valuck BW, Gilliam JK et al. Activation of CD74 inhibits migration of human mesenchymal stem cells. In Vitro Cell Dev Biol Anim 2010;46:566-572.
20. Vandenbark AA, Meza-Romero R, Benedek G et al. A novel regulatory pathway for autoimmune disease: Binding of partial MHC class II constructs to monocytes reduces CD74 expression and induces both specific and bystander T-cell tolerance. J Autoimmun 2013; 40:96-110.
21. Hynes RO, Naba A. Overview of the matrisome: An inventory of extracellular matrix constituents and functions. Cold Spring Harb Perspect Biol 2012;4:a004903.
22. Burrows GG, Chou YK, Wang C et al. Rudimentary TCR signaling triggers default IL-10 secretion by human Th1 cells. J Immunol 2001; 167:4386-4395.
23. Huan J, Kaler LJ, Mooney JL et al. MHC class II derived recombinant T cell receptor ligands protect DBA/1LacJ mice from collageninduced arthritis. J Immunol 2008;180:1249-1257.
24. Chang JW, Mechling DE, Bachinger HP et al. Design, engineering, and production of human recombinant t cell receptor ligands derived from human leukocyte antigen DR2. J Biol Chem 2001;276:24170-24176.
25. Burrows GG, Vandenbark AA, inventors; Oregon Health Sciences University, assignee. Recombinant MHC molecules useful for manipulation of antigen-specific T-cells. US patent 6/270/772. August 7, 2001.
26. Huan J, Meza-Romero R, Mooney JL et al. Single-chain recombinant HLA-DQ2.5/peptide molecules block alpha2-gliadin-specific pathogenic CD4+ T-cell proliferation and attenuate production of inflammatory cytokines: A potential therapy for celiac disease. Mucosal Immunol 2011;4:112-120.
27. Yadav V, Bourdette DN, Bowen JD et al. Recombinant T-cell receptor ligand (RTL) for treatment of multiple sclerosis: A doubleblind, placebo-controlled, phase 1, dose-escalation study. Autoimmune Dis 2012;2012: 954739.
28. Dominici M, Le Blanc K, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells: The International Society for Cellular Therapy position statement. Cytotherapy 2006;8:315-317.
29. Schwartz RE, Reyes M, Koodie L et al. Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells. J Clin Invest 2002;109:1291-1302.
30. Boozer S, Lehman N, Lakshmipathy U et al. Global characterization and genomic stability of human Multi Stem, a multipotent adult progenitor cell. J Stem Cells 2009;4:17-28.
31. Bassnett S, Wilmarth PA, David LL. The membrane proteome of the mouse lens fiber cell. Mol Vis 2009;15:2448-2463.
32. Wilmarth PA, Tanner S, Dasari S et al. Age-related changes in human crystallins determined from comparative analysis of posttranslational modifications in young and aged lens: Does deamidation contribute to crystallin insolubility? J Proteome Res 2006;5:2554-2566.
33. Wilmarth PA, Riviere MA, David LL. Techniques for accurate protein identification in shotgun proteomic studies of human, mouse, bovine, and chicken lenses. J Ocul Biol Dis Infor 2009;2:223-234.
34. Keller A, Nesvizhskii AI, Kolker E et al. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem 2002; 74:5383-5392.
35. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4:44-57.
36. Dennis G Jr., Sherman BT, Hosack DA et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 2003;4:P3.
37. Zhan X, Desiderio DM. Signaling pathway networks mined from human pituitary adenoma proteomics data. BMC Med Genomics 2010;3:13.
38. Finoulst I, Vink P, Rovers E et al. Identification of low abundant secreted proteins and peptides from primary culture supernatants of human T-cells. J Proteomics 2011;75:23-33.
39. Smith MP, Wood SL, Zougman A et al. A systematic analysis of the effects of increasing degrees of serum immunodepletion in terms of depth of coverage and other key aspects in top-down and bottom-up proteomic analyses. Proteomics 2011;11:2222-2235.
40. Horie H, Kadoya T, Hikawa N et al. Oxidized galectin-1 stimulates macrophages to promote axonal regeneration in peripheral nerves after axotomy. J Neurosci 2004;24: 1873-1880.
41. Eichelbaum K, Winter M, Berriel Diaz M et al. Selective enrichment of newly synthesized proteins for quantitative secretome analysis. Nat Biotechnol 2012;30:984-990.
42. Wolf D, Wolf AM. Mesenchymal stem cells as cellular immunosuppressants. Lancet 2008;371:1553-1554.
43. Maziarz RT, Devos T, Bachier C et al. Prophylaxis of acute GVHD using Multistem® stromal cell Therapy: Preliminary results after administration of single or multiple doses in a Phase 1 trial. Biol Blood Marrow Transplant 2012;18(suppl 1):S264-S265.
44. Penn MS, Ellis S, Gandhi S et al. Adventitial delivery of an allogeneic bone marrow-derived adherent stem cell in acute myocardial infarction: Phase I clinical study. Circ Res 2012; 110:304-311.
45. Aranguren XL, Luttun A, Clavel C et al. In vitro and in vivo arterial differentiation of human multipotent adult progenitor cells. Blood 2007;109:2634-2642.
46. Aranguren XL, Pelacho B, Penuelas I et al. MAPC transplantation confers a more durable benefit than AC133+cell transplantation in severe hind limb ischemia. Cell Transplant 2011; 20:259-269.
47. Lehman N, Cutrone R, Raber A et al. Development of a surrogate angiogenic potency assay for clinical-grade stem cell production. Cytotherapy 2012;14:994-1004.
48. Walker PA, Bedi SS, Shah SK et al. Intravenous multipotent adult progenitor cell therapy after traumatic brain injury: Modulation of the resident microglia population. J Neuroinflammation 2012;9:228.
49. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: Rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000;95:2754-2759.
50. Eggenhofer E, Benseler V, Kroemer A et al. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front Immunol 2012;3:297.
51. Wang N, Shao Y, Mei Y et al. Novel mechanism for mesenchymal stem cells in attenuating peritoneal adhesion: Accumulating in the lung and secreting tumor necrosis factor α-stimulating gene-6. Stem Cell Res Ther 2012; 3:51.
52. Roddy GW, Oh JY, Lee RH et al. Action at a distance: Systemically administered adult stem/progenitor cells (MSCs) reduce inflammatory damage to the cornea without engraftment and primarily by secretion of TNF-alpha stimulated gene/protein 6. Stem Cells 2011;29: 1572-1579.
53. Zanotti L, Sarukhan A, Dander E et al. Encapsulated mesenchymal stem cells for in vivo immunomodulation. Leukemia 2013;27: 500-503.
54. Rifkin DB. Latent transforming growth factor-beta (TGF-beta) binding proteins: Orchestrators of TGF-beta availability. J Biol Chem 2005;280:7409-7412.
55. Reinboth B, Thomas J, Hanssen E et al. Beta ig-h3 interacts directly with biglycan and decorin, promotes collagen VI aggregation, and participates in ternary complexing with these macromolecules. J Biol Chem 2006;281: 7816-7824.
56. Nacu N, Luzina IG, Highsmith K et al. Macrophages produce TGF-beta-induced (beta-ig-h3) following ingestion of apoptotic cells and regulate MMP14 levels and collagen turnover in fibroblasts. J Immunol 2008;180: 5036-5044.
57. Rios HF, Ma D, Xie Y et al. Periostin is essential for the integrity and function of the periodontal ligament during occlusal loading in mice. J Periodontol 2008;79:1480-1490.
58. Sheppard D. Epithelial integrins. Bioessays 1996;18:655-660.
59. Woodruff PG, Boushey HA, Dolganov GM, et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci USA 2007;104:15858-15863.
60. Gordon ED, Sidhu SS, Wang ZE et al. A protective role for periostin and TGF-β in IgEmediated allergy and airway hyperresponsiveness. Clin Exp Allergy 2012;42:144-155.
61. Sidhu SS, Yuan S, Innes AL et al. Roles of epithelial cell-derived periostin in TGF-beta activation, collagen production, and collagen gel elasticity in asthma. Proc Natl Acad Sci USA 2010;107:14170-14175.
62. Bechtel M, Keller MV, Bloch W, et al. Different domains in nidogen-1 and nidogen-2 drive basement membrane formation in skin organotypic cocultures. FASEB J 2012;26: 3637-3648.
63. Ho MS, Bose K, Mokkapati S et al. Nidogens: Extracellular matrix linker molecules. Microsc Res Tech 2008;71:387-395.
64. Wu Y, Wu J, Lee DY et al. Versican protects cells from oxidative stress-induced apoptosis. Matrix Biol 2005;24:3-13.
65. Zhang Z, Miao L, Wang L. Inflammation amplification by versican: The first mediator. Int J Mol Sci 2012;13:6873-6882.
66. Nakada M, Miyamori H, Yamashita J et al. Testican 2 abrogates inhibition of membranetype matrix metalloproteinases by other testican family proteins. Cancer Res 2003;63: 3364-3369.
67. Nakada M, Yamada A, Takino T et al. Suppression of membrane-type 1 matrix metalloproteinase (MMP)-mediated MMP-2 activation and tumor invasion by testican 3 and its splicing variant gene product, N-Tes. Cancer Res 2001;61:8896-8902.
68. Bocock JP, Edgell CJ, Marr HS et al. Human proteoglycan testican-1 inhibits the lysosomal cysteine protease cathepsin L. Eur J Biochem 2003;270:4008-4015.
69. Hata S, Fujishige S, Araki Y et al. Alcadein cleavages by amyloid beta-precursor protein (APP) alpha-and gamma-secretases generate small peptides, p3-Alcs, indicating Alzheimer disease-related gamma-secretase dysfunction. J Biol Chem 2009;284:36024-36033.
70. Maruta C, Saito Y, Hata S et al. Constitutive cleavage of the single-pass transmembrane protein alcadeinα prevents aberrant peripheral retention of Kinesin-1. PLoS One 2012; 7:e43058.
71. Kazanecki CC, Uzwiak DJ, Denhardt DT. Control of osteopontin signaling and function by post-translational phosphorylation and protein folding. J Cell Biochem 2007;102:912-924.
72. Uede T, Katagiri Y, Iizuka J et al. Osteopontin, a coordinator of host defense system: A cytokine or an extracellular adhesive protein? Microbiol Immunol 1997;41:641-648.
73. Singh M, Ananthula S, Milhorn DM et al. Osteopontin: A novel inflammatory mediator of cardiovascular disease. Front Biosci 2007; 12:214-221.
74. Wang KX, Denhardt DT. Osteopontin: Role in immune regulation and stress responses. Cytokine Growth Factor Rev 2008;19: 333-345.
75. Scatena M, Liaw L, Giachelli CM. Osteopontin: A multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 2007;27:2302-2309.
76. Prudova A, Auf dem Keller U, Butler GS et al. Multiplex N-terminome analysis of MMP-2 and MMP-9 substrate degradomes by iTRAQTAILS quantitative proteomics. Mol Cell Proteomics 2010;9:894-911.
77. Winberg JO, Kolset SO, Berg E et al. Macrophages secrete matrix metalloproteinase 9 covalently linked to the core protein of chondroitin sulphate proteoglycans. J Mol Biol 2000;304:669-680.
78. Winberg JO, Berg E, Kolset SO et al. Calcium-induced activation and truncation of promatrix metalloproteinase-9 linked to the core protein of chondroitin sulfate proteoglycans. Eur J Biochem 2003;270:3996-4007.
79. Kolset SO, Pejler G. Serglycin: A structural and functional chameleon with wide impact on immune cells. J Immunol 187:4927-4933.
80. Grossman M, Tworowski D, Dym O et al. The intrinsic protein flexibility of endogenous protease inhibitor TIMP-1 controls its binding interface and affects its function. Biochemistry 2010;49:6184-6192.
81. Lee MH, Rapti M, Knauper V et al. Threonine 98, the pivotal residue of tissue inhibitor of metalloproteinases (TIMP)-1 in metalloproteinase recognition. J Biol Chem 2004;279: 17562-17569.
82. Chirco R, Liu XW, Jung KK et al. Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev 2006;25:99-113.
83. Itoh Y, Ito A, Iwata K et al. Plasma membrane-bound tissue inhibitor of metalloproteinases (TIMP)-2 specifically inhibits matrix metalloproteinase 2 (gelatinase A) activated on the cell surface. J Biol Chem 1998;273:24360-24367.
84. Cuzner ML, Gveric D, Strand C et al. The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: Comparison of stages in lesion evolution. J Neuropathol Exp Neurol 1996;55: 1194-1204.
85. Degryse B, Neels JG, Czekay RP et al. The low density lipoprotein receptor-related protein is a motogenic receptor for plasminogen activator inhibitor-1. J Biol Chem 2004;279: 22595-22604.
86. Bristow CL, Babayeva MA, La Brunda M, et al. α1Proteinase inhibitor regulates CD4+ lymphocyte levels and is rate limiting in HIV-1 disease. PLoS One 2012;7:e31383.
87. van Mourik JA, Lawrence DA, Loskutoff DJ. Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J Biol Chem 1984;259:14914-14921.
88. Lambers JW, Cammenga M, Konig BW et al. Activation of human endothelial cell-type plasminogen activator inhibitor (PAI-1) by negatively charged phospholipids. J Biol Chem 1987;262:17492-17496.
89. Vadon-Le Goff S, Kronenberg D, Bourhis JM et al. Procollagen C-proteinase enhancer stimulates procollagen processing by binding to the C-propeptide region only. J Biol Chem 2011;286:38932-38938.
90. Hopkins DR, Keles S, Greenspan DS. The bone morphogenetic protein 1/Tolloid-like metalloproteinases. Matrix Biol 2007;26:508-523.
91. Waldburger JM, Masternak K, Muhlethaler-Mottet A et al. Lessons from the bare lymphocyte syndrome: Molecular mechanisms regulating MHC class II expression. Immunol Rev 2000;178:148-165.
92. Castonguay R, Werner ED, Matthews RG et al. Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth. J Biol Chem 2011; 286:30034-30046.
93. Rivera LB, Brekken RA. SPARC promotes pericyte recruitment via inhibition of endoglindependent TGF-β1 activity. J Cell Biol 2011; 193:1305-1319.
94. Patterson J, Hubbell JA. SPARC-derived protease substrates to enhance the plasmin sensitivity of molecularly engineered PEG hydrogels. Biomaterials 2011;32:1301-1310.
95. McCurdy SM, Dai Q, Zhang J et al. SPARC mediates early extracellular matrix remodeling following myocardial infarction. Am J Physiol Heart Circ Physiol 2011;301:H497-H505.
96. Girotti MR, Fernandez M, Lopez JA et al. SPARC promotes cathepsin B-mediated melanoma invasiveness through a collagen I/α2β1 integrin axis. J Invest Dermatol 2011;131: 2438-2447.
97. Murakami K, Tanaka M, Usui T et al. Follistatin-related protein/follistatin-like 1 evokes an innate immune response via CD14 and tolllike receptor 4. FEBS Lett 2012;586:319-324.
98. Hiraiwa N, Yabuta T, Yoritomi K et al. Transactivation of the fucosyltransferase VII gene by human T-cell leukemia virus type 1 Tax through a variant cAMP-responsive element. Blood 2003;101:3615-3621.
99. Malapeira J, Esselens C, Bech-Serra JJ et al. ADAM17 (TACE) regulates TGFbeta signaling through the cleavage of vasorin. Oncogene 2011;30:1912-1922.
100. Caccia D, Zanetti Domingues L, Micciche F et al. Secretome compartment is a valuable source of biomarkers for cancer-relevant pathways. J Proteome Res 2011;10:4196-4207.
101. Sun T, Adra S, Smallwood R et al. Exploring hypotheses of the actions of TGF-beta1 in epidermal wound healing using a 3D computational multiscale model of the human epidermis. PLoS One 2009;4:e8515.
102. Grootaert C, Van de Wiele T, Verstraete W et al. Angiopoietin-like protein 4: Health effects, modulating agents and structure-function relationships. Expert Rev Proteomics 2012;9:181-199.
103. Sioud M, Mobergslien A, Boudabous A et al. Mesenchymal stem cell-mediated T cell suppression occurs through secreted galectins. Int J Oncol 2011;38:385-390.
104. Wang J, Lu ZH, Gabius HJ et al. Crosslinking of GM1 ganglioside by galectin-1 mediates regulatory T cell activity involving TRPC5 channel activation: Possible role in suppressing experimental autoimmune encephalomyelitis. J Immunol 2009;182:4036-4045.
105. Toscano MA, Bianco GA, Ilarregui JM et al. Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nat Immunol 2007;8: 825-834.
106. Patnaik SK, Potvin B, Carlsson S et al. Complex N-glycans are the major ligands for galectin-1,-3, and-8 on Chinese hamster ovary cells. Glycobiology 2006;16:305-317.
107. Babic AM, Chen CC, Lau LF. Fisp12/ mouse connective tissue growth factor mediates endothelial cell adhesion and migration through integrin αvβ3, promotes endothelial cell survival, and induces angiogenesis in vivo. Mol Cell Biol 1999;19:2958-2966.
108. Hashimoto G, Inoki I, Fujii Y et al. Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165. J Biol Chem 2002;277:36288-36295.
109. Jun JI, Lau LF. Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets. Nat Rev Drug Discov 2011;10: 945-963.
110. Gui Y, Murphy LJ. Interaction of insulinlike growth factor binding protein-3 with latent transforming growth factor-beta binding protein-1. Mol Cell Biochem 2003;250:189-195.
111. Hong L, Sun H, Lv X et al. Expression of periostin in the serum of NSCLC and its function on proliferation and migration of human lung adenocarcinoma cell line (A549) in vitro. Mol Biol Rep 2010;37:2285-2293.
112. Mor-Vaknin N, Punturieri A, Sitwala K et al. Vimentin is secreted by activated macrophages. Nat Cell Biol 2003;5:59-63.
113. Kwak HI, Kang H, Dave JM et al. Calpainmediated vimentin cleavage occurs upstream of MT1-MMP membrane translocation to facilitate endothelial sprout initiation. Angiogenesis 2012;15:287-303.
114. Komura K, Ise H, Akaike T. Dynamic behaviors of vimentin induced by interaction with GlcNAc molecules. Glycobiology 2012;22: 1741-1759.
115. Ise H, Kobayashi S, Goto M, et al. Vimentin and desmin possess GlcNAc-binding lectinlike properties on cell surfaces. Glycobiology 2010;20:843-864.
116. Czopik AK, Bynoe MS, Palm N et al. Semaphorin 7A is a negative regulator of T cell responses. Immunity 2006;24:591-600.
117. Crosnier C, Stamataki D, Lewis J. Organizing cell renewal in the intestine: Stem cells, signals and combinatorial control. Nat Rev Genet 2006;7:349-359.
118. van Kilsdonk JW, van Kempen LC, van Muijen GN et al. Soluble adhesion molecules in human cancers: Sources and fates. Eur J Cell Biol 89:415-427.
119. Lunter PC, van Kilsdonk JW, van Beek H et al. Activated leukocyte cell adhesion molecule (ALCAM/CD166/MEMD), a novel actor in invasive growth, controls matrix metalloproteinase activity. Cancer Res 2005;65:8801-8808.
120. Manfredi AA, Rovere-Querini P, Bottazzi B et al. Pentraxins, humoral innate immunity and tissue injury. Curr Opin Immunol 2008; 20:538-544.
121. Li X, Ni R, Chen J et al. The presence of IGHG1 in human pancreatic carcinomas is associated with immune evasion mechanisms. Pancreas 2011;40:753-761.
122. McCormick MM, Rahimi F, Bobryshev YV et al. S100A8 and S100A9 in human arterial wall. Implications for atherogenesis. J Biol Chem 2005;280:41521-41529.
123. Smith SM, Thomas CE, Birk DE. Pericellular proteins of the developing mouse tendon: A proteomic analysis. Connect Tissue Res 2012; 53:2-13.
124. Adlerova L, Bartoskova A, Faldyna M. Lactoferrin: A review. Veterinarni Medicina 2008;53:457-468.
125. Wang HW, Babic AM, Mitchell HA et al. Elevated soluble ICAM-1 levels induce immune deficiency and increase adiposity in mice. FASEB J 2005;19:1018-1020.
126. Weber C, Kraemer S, Drechsler M et al. Structural determinants of MIF functions in CXCR2-mediated inflammatory and atherogenic leukocyte recruitment. Proc Natl Acad Sci USA 2008;105:16278-16283.
127. Kohler A, De Filippo K, Hasenberg M et al. G-CSF-mediated thrombopoietin release triggers neutrophil motility and mobilization from bone marrow via induction of Cxcr2 ligands. Blood 2011;117:4349-4357.
128. Hyun YM, Sumagin R, Sarangi PP et al. Uropod elongation is a common final step in leukocyte extravasation through inflamed vessels. J Exp Med 2012;209:1349-1362.